Vibrio Diagnostic Testing Market: US, Europe, Japan

September 2017 | 200 pages | ID: V3A9FE524A2EN
Venture Planning Group

Abstracts

The report presents a detailed analysis of the Vibrio diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Vibrio definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments:

• Hospitals
• Commercial/Private Labs
• Physician Offices
• Public Health Labs

Also, the report examines the market applications of DNA Probes, Monoclonal Antibodies, Immunoassays, IT and other technologies; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning issues and concerns.

Contains 200 pages and 7 tables

Contents

I. INTRODUCTION

II. Worldwide Test Overview, Technologies and Instrumentation
A. Background, Diagnostic Tests, Vaccines and Drugs
B. Instrumentation Review: Operating Characteristics, Features and Selling Princes of Leading Infectious Disease Automated and Semiautomated Analyzers
C. Emerging Infectious Disease Diagnostic Technologies
  1. MOLECULAR DIAGNOSTICS
  2. MONOCLONAL ANTIBODIES
  3. IMMUNOASSAYS
  4. DIFFERENTIAL LIGHT SCATTERING
  5. INFORMATION TECHNOLOGY
  6. ARTIFICIAL INTELLIGENCE
  7. LIPOSOMES
  8. FLOW CYTOMETRY
  9. CHROMATOGRAPHY
  10. DIAGNOSTIC IMAGING
  11. GEL MICRODROPLETS
  12. OTHERS
D. Personal Testing
III. Country Analyses: Sales and Volume Forecasts

IV. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

A. Instrumentation
B. Reagent Kits and Test Systems/Panels
C. Information Technology
D. Auxiliary Products

V. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

VI. ALTERNATIVE MARKET PENETRATION STRATEGIES

A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized TESTING MARKETS

VII. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges

VIII. COMPETITIVE ASSESSMENTS

Abbott
Affymetrix
Beckman Coulter/Danaher
Becton Dickinson
bioMerieux
BioRad
Cepheid
Diamedix/Erba
DiaSorin
Eiken Chemical
Elitech Group
Enzo Biochem
Fujirebio
Grifols
Hologic/GenProbe
ID Biomedical/GSK
Kreatech/Leica
Lonza
OrthoClinical Diagnostics
Qiagen
Roche
Scienion
Sequenom
SeraCare
Siemens
Takara Bio
Thermo Fisher/Life Technology
Wallac/PE
Wako